{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:06:31Z","timestamp":1789632391126,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41401-026-01788-8","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T08:50:25Z","timestamp":1774342225000},"page":"2996-3008","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["BMAL1 silencing as a promising chemosensitizing strategy for triple-negative breast cancer"],"prefix":"10.1038","volume":"47","author":[{"given":"Lu-yi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-han","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-jing","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-yue","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"1788_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0156-4","volume":"50","author":"TJ Ma","year":"2018","unstructured":"Ma TJ, Zhang ZW, Lu YL, Zhang YY, Tao DC, Liu YQ, et al. CLOCK and BMAL1 stabilize and activate RHOA to promote F-actin formation in cancer cells. Exp Mol Med. 2018;50:1\u201315.","journal-title":"Exp Mol Med"},{"key":"1788_CR2","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1073\/pnas.0812638106","volume":"106","author":"TH Kang","year":"2009","unstructured":"Kang TH, Reardon JT, Kemp M, Sancar A. Circadian oscillation of nucleotide excision repair in mammalian brain. Proc Natl Acad Sci USA. 2009;106:2864\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1788_CR3","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.canlet.2015.12.002","volume":"371","author":"W Jiang","year":"2016","unstructured":"Jiang W, Zhao S, Jiang X, Zhang E, Hu G, Hu B, et al. The circadian clock gene Bmal1 acts as a potential anti-oncogene in pancreatic cancer by activating the p53 tumor suppressor pathway. Cancer Lett. 2016;371:314\u201325.","journal-title":"Cancer Lett"},{"key":"1788_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-019-0902-2","volume":"19","author":"J Wang","year":"2019","unstructured":"Wang J, Li S, Li X, Li B, Li Y, Xia K, et al. Circadian protein BMAL1 promotes breast cancer cell invasion and metastasis by up-regulating matrix metalloproteinase9 expression. Cancer Cell Int. 2019;19:182.","journal-title":"Cancer Cell Int"},{"key":"1788_CR5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2214829120","volume":"120","author":"M Qu","year":"2023","unstructured":"Qu M, Zhang G, Qu H, Vu A, Wu R, Tsukamoto H, et al. Circadian regulator BMAL1::CLOCK promotes cell proliferation in hepatocellular carcinoma by controlling apoptosis and cell cycle. Proc Natl Acad Sci USA. 2023;120:e2214829120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1788_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nature25170","volume":"553","author":"G Sulli","year":"2018","unstructured":"Sulli G, Rommel A, Wang X, Kolar MJ, Puca F, Saghatelian A, et al. Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence. Nature. 2018;553:351\u20135.","journal-title":"Nature"},{"key":"1788_CR7","doi-asserted-by":"publisher","first-page":"E12305","DOI":"10.1073\/pnas.1816411115","volume":"115","author":"M Qu","year":"2018","unstructured":"Qu M, Duffy T, Hirota T, Kay SA. Nuclear receptor HNF4A transrepresses CLOCK: BMAL1 and modulates tissue-specific circadian networks. Proc Natl Acad Sci USA. 2018;115:E12305\u2013E12312.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1788_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19:91\u2013113.","journal-title":"Nat Rev Clin Oncol"},{"key":"1788_CR9","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41586-019-1056-z","volume":"569","author":"F Bertucci","year":"2019","unstructured":"Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, et al. Genomic characterization of metastatic breast cancers. Nature. 2019;569:560\u20134.","journal-title":"Nature"},{"key":"1788_CR10","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1200\/JCO.2017.76.0033","volume":"36","author":"Stover","year":"2018","unstructured":"Stover, Parsons HA DG, Ha G, Freeman SS, Barry WT, Guo H, et al. Association of cell-free DNA tumor fraction and somatic copy number alterations with survival in metastatic triple-negative breast cancer. J Clin Oncol. 2018;36:543\u201353.","journal-title":"J Clin Oncol"},{"key":"1788_CR11","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature. 2005;434:913\u20137.","journal-title":"Nature"},{"key":"1788_CR12","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917\u201321.","journal-title":"Nature"},{"key":"1788_CR13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA Mutation. N Engl J Med. 2017;377:523\u201333.","journal-title":"N Engl J Med"},{"key":"1788_CR14","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gon\u00e7alves A, Lee KH, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA Mutation. N Engl J Med. 2018;379:753\u201363.","journal-title":"N Engl J Med"},{"key":"1788_CR15","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.tig.2016.06.007","volume":"32","author":"R Bhargava","year":"2016","unstructured":"Bhargava R, Onyango DO, Stark JM. Regulation of single-strand annealing and its role in genome maintenance. Trends Genet. 2016;32:566\u201375.","journal-title":"Trends Genet"},{"key":"1788_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23806-5","volume":"12","author":"A Lezaja","year":"2021","unstructured":"Lezaja A, Panagopoulos A, Wen Y, Carvalho E, Imhof R, Altmeyer M. RPA shields inherited DNA lesions for post-mitotic DNA synthesis. Nat Commun. 2021;12:3827.","journal-title":"Nat Commun"},{"key":"1788_CR17","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/jcpt.13349","volume":"46","author":"C Wang","year":"2021","unstructured":"Wang C, Li J. Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29 randomized controlled trials. J Clin Pharm Ther. 2021;46:571\u201384.","journal-title":"J Clin Pharm Ther"},{"key":"1788_CR18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.ygyno.2017.12.029","volume":"148","author":"HJ Gray","year":"2018","unstructured":"Gray HJ, Bell-McGuinn K, Fleming GF, Cristea M, Xiong H, Sullivan D, et al. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gynecol Oncol. 2018;148:507\u201314.","journal-title":"Gynecol Oncol"},{"key":"1788_CR19","doi-asserted-by":"publisher","first-page":"18790","DOI":"10.1073\/pnas.1115249108","volume":"108","author":"S Gaddameedhi","year":"2011","unstructured":"Gaddameedhi S, Selby CP, Kaufmann WK, Smart RC, Sancar A. Control of skin cancer by the circadian rhythm. Proc Natl Acad Sci USA. 2011;108:18790\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1788_CR20","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1073\/pnas.0915085107","volume":"107","author":"TH Kang","year":"2010","unstructured":"Kang TH, Lindsey-Boltz LA, Reardon JT, Sancar A. Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase. Proc Natl Acad Sci USA. 2010;107:4890\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1788_CR21","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/s41388-023-02603-y","volume":"42","author":"C Zhang","year":"2023","unstructured":"Zhang C, Chen L, Sun L, Jin H, Ren K, Liu S, et al. BMAL1 collaborates with CLOCK to directly promote DNA double-strand break repair and tumor chemoresistance. Oncogene. 2023;42:967\u201379.","journal-title":"Oncogene"},{"key":"1788_CR22","doi-asserted-by":"publisher","first-page":"22935","DOI":"10.1002\/jcp.28855","volume":"234","author":"Z Saltanatpour","year":"2019","unstructured":"Saltanatpour Z, Johari B, Alizadeh A, Lotfinia M, Majidzadeh AK, Nikbin B, et al. Enrichment of cancer stem-like cells by the induction of epithelial-mesenchymal transition using lentiviral vector carrying E-cadherin shRNA in HT29 cell line. J Cell Physiol. 2019;234:22935\u201346.","journal-title":"J Cell Physiol"},{"key":"1788_CR23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3390\/v12050513","volume":"12","author":"KHD Crawford","year":"2020","unstructured":"Crawford KHD, Eguia R, Dingens AS, Loes AN, Malone KD, Wolf CR, et al. Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays. Viruses. 2020;12:513.","journal-title":"Viruses"},{"key":"1788_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2025.103708","volume":"6","author":"SLK Weber","year":"2025","unstructured":"Weber SLK, Heinzel T, Iyer-Bierhoff A. Protocol for ecotropic pseudotyped lentiviral transduction of \u201cmurinized\u201d human cells while decreasing risk of infection for laboratory personnel. STAR Protoc. 2025;6:103708.","journal-title":"STAR Protoc"},{"key":"1788_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20892\/j.issn.2095-3941.2022.0474","volume":"20","author":"C Huang","year":"2023","unstructured":"Huang C, Zhang C, Cao Y, Li J, Bi F. Major roles of the circadian clock in cancer. Cancer Biol Med. 2023;20:1\u201324.","journal-title":"Cancer Biol Med"},{"key":"1788_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.537247","volume":"10","author":"F Xie","year":"2020","unstructured":"Xie F, Wang L, Liu Y, Liu Z, Zhang Z, Pei J, et al. ASMT regulates tumor metastasis through the circadian clock system in triple-negative breast cancer. Front Oncol. 2020;10:537247.","journal-title":"Front Oncol"},{"key":"1788_CR27","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1158\/2159-8290.CD-19-0215","volume":"9","author":"Z Dong","year":"2019","unstructured":"Dong Z, Zhang G, Qu M, Gimple RC, Wu Q, Qiu Z, et al. Targeting glioblastoma stem cells through disruption of the circadian clock. Cancer Discov. 2019;9:1556\u201373.","journal-title":"Cancer Discov"},{"key":"1788_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb0738","volume":"371","author":"Aziz Sancar","year":"2021","unstructured":"Sancar Aziz, Van Gelder RussellN. Clocks, cancer, and chronochemotherapy. Science. 2021;371:eabb0738.","journal-title":"Science"},{"key":"1788_CR29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.mce.2017.06.004","volume":"454","author":"NL Ka","year":"2017","unstructured":"Ka NL, Na TY, Lee MO. NR1D1 enhances oxidative DNA damage by inhibiting PARP1 activity. Mol Cell Endocrinol. 2017;454:87\u201392.","journal-title":"Mol Cell Endocrinol"},{"key":"1788_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188521","volume":"1875","author":"J Jin","year":"2021","unstructured":"Jin J, Tao Z, Cao J, Li T, Hu X. DNA damage response inhibitors: an avenue for TNBC treatment. Biochim Biophys Acta Rev Cancer. 2021;1875:188521.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1788_CR31","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.canlet.2020.10.016","volume":"497","author":"X Bai","year":"2021","unstructured":"Bai X, Ni J, Beretov J, Graham P, Li Y. Triple-negative breast cancer therapeutic resistance: Where is the Achilles\u2019 heel? Cancer Lett. 2021;497:100\u201311.","journal-title":"Cancer Lett"},{"key":"1788_CR32","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","volume":"29","author":"C Cruz","year":"2018","unstructured":"Cruz C, Castroviejo-Bermejo M, Guti\u00e9rrez-Enr\u00edquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, et al. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol. 2018;29:1203\u201310.","journal-title":"Ann Oncol"},{"key":"1788_CR33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jmb.2007.07.068","volume":"373","author":"KM Sleeth","year":"2007","unstructured":"Sleeth KM, S\u00f8rensen CS, Issaeva N, Dziegielewski J, Bartek J, Helleday T. RPA mediates recombination repair during replication stress and is displaced from DNA by checkpoint signalling in human cells. J Mol Biol. 2007;373:38\u201347.","journal-title":"J Mol Biol"},{"key":"1788_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188716","volume":"1877","author":"M Kciuk","year":"2022","unstructured":"Kciuk M, Gieleci\u0144ska A, Mujwar S, Mojzych M, Kontek R. Cyclin-dependent kinases in DNA damage response. Biochim Biophys Acta Rev Cancer. 2022;1877:188716.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1788_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05392-6","volume":"13","author":"H Xu","year":"2022","unstructured":"Xu H, Zhang J, Zheng X, Tan P, Xiong X, Yi X, et al. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXR\u03b1\/FOXM1 pathway independently of REV-ERBs. Cell Death Dis. 2022;13:949.","journal-title":"Cell Death Dis"},{"key":"1788_CR36","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/jb\/mvq069","volume":"148","author":"ZL Zeng","year":"2010","unstructured":"Zeng ZL, Wu MW, Sun J, Sun YL, Cai YC, Huang YJ, et al. Effects of the biological clock gene Bmal1 on tumour growth and anti-cancer drug activity. J Biochem. 2010;148:319\u201326.","journal-title":"J Biochem"},{"key":"1788_CR37","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1158\/1078-0432.CCR-13-0171","volume":"20","author":"ZL Zeng","year":"2014","unstructured":"Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P, et al. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clin Cancer Res. 2014;20:1042\u201352.","journal-title":"Clin Cancer Res"},{"key":"1788_CR38","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/cells10010046","volume":"10","author":"N Datta","year":"2020","unstructured":"Datta N, Chakraborty S, Basu M, Ghosh MK. Tumor suppressors having oncogenic functions: the double agents. Cells. 2020;10:46.","journal-title":"Cells"},{"key":"1788_CR39","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.leukres.2005.04.023","volume":"29","author":"AL Gartel","year":"2005","unstructured":"Gartel AL. The conflicting roles of the cdk inhibitor p21(CIP1\/WAF1) in apoptosis. Leuk Res. 2005;29:1237\u20138.","journal-title":"Leuk Res"},{"key":"1788_CR40","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1615\/CritRevEukaryotGeneExpr.v26.i1.60","volume":"26","author":"A Parveen","year":"2016","unstructured":"Parveen A, Akash MS, Rehman K, Kyunn WW. Dual role of p21 in the progression of cancer and its treatment. Crit Rev Eukaryot Gene Expr. 2016;26:49\u201362.","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"1788_CR41","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.tig.2018.09.005","volume":"34","author":"J Yeung","year":"2018","unstructured":"Yeung J, Naef F. Rhythms of the genome: circadian dynamics from chromatin topology, tissue-specific gene expression, to behavior. Trends Genet. 2018;34:915\u201326.","journal-title":"Trends Genet"},{"key":"1788_CR42","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.trecan.2019.07.002","volume":"5","author":"G Sulli","year":"2019","unstructured":"Sulli G, Lam MTY, Panda S. Interplay between circadian clock and cancer: new frontiers for cancer treatment. Trends Cancer. 2019;5:475\u201394.","journal-title":"Trends Cancer"},{"key":"1788_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120835","volume":"605","author":"R Chadar","year":"2021","unstructured":"Chadar R, Afsana, Kesharwani P. Nanotechnology-based siRNA delivery strategies for treatment of triple negative breast cancer. Int J Pharm. 2021;605:120835.","journal-title":"Int J Pharm"},{"key":"1788_CR44","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.54090","volume":"9","author":"RK Alexander","year":"2020","unstructured":"Alexander RK, Liou YH, Knudsen NH, Starost KA, Xu C, Hyde AL, et al. Bmal1 integrates mitochondrial metabolism and macrophage activation. Elife. 2020;9:e54090.","journal-title":"Elife"},{"key":"1788_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.108808","volume":"34","author":"TB Branigan","year":"2021","unstructured":"Branigan TB, Kozono D, Schade AE, Deraska P, Rivas HG, Sambel L, et al. MMB-FOXM1-driven premature mitosis is required for CHK1 inhibitor sensitivity. Cell Rep. 2021;34:108808.","journal-title":"Cell Rep"},{"key":"1788_CR46","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/sj.onc.1210707","volume":"27","author":"LM Lau","year":"2008","unstructured":"Lau LM, Nugent JK, Zhao X, Irwin MS. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene. 2008;27:997\u20131003.","journal-title":"Oncogene"},{"key":"1788_CR47","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1158\/2159-8290.CD-22-1131","volume":"13","author":"CM Adams","year":"2023","unstructured":"Adams CM, Mitra R, Xiao Y, Michener P, Palazzo J, Chao A, et al. Targeted MDM2 degradation reveals a new vulnerability for p53-inactivated triple-negative breast cancer. Cancer Discov. 2023;13:1210\u201329.","journal-title":"Cancer Discov"},{"key":"1788_CR48","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.3390\/ijms26031078","volume":"26","author":"JL On","year":"2025","unstructured":"On JL, Ghaderi S, Rittmann C, Hoffmann G, Gier F, Woloschin V, et al. Pharmacological inhibition of MDM2 induces apoptosis in p53-mutated triple-negative breast cancer. Int J Mol Sci. 2025;26:1078.","journal-title":"Int J Mol Sci"},{"key":"1788_CR49","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.cmet.2015.08.006","volume":"22","author":"D Jacobi","year":"2015","unstructured":"Jacobi D, Liu S, Burkewitz K, Kory N, Knudsen NH, Alexander RK, et al. Hepatic Bmal1 regulates rhythmic mitochondrial dynamics and promotes metabolic fitness. Cell Metab. 2015;22:709\u201320.","journal-title":"Cell Metab"},{"key":"1788_CR50","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1016\/j.celrep.2018.10.068","volume":"25","author":"X Zhong","year":"2018","unstructured":"Zhong X, Yu J, Frazier K, Weng X, Li Y, Cham CM, et al. Circadian clock regulation of hepatic lipid metabolism by modulation of m6A mRNA methylation. Cell Rep. 2018;25:1816\u201328.","journal-title":"Cell Rep"},{"key":"1788_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114380","volume":"43","author":"R Van Drunen","year":"2024","unstructured":"Van Drunen R, Dai Y, Wei H, Fekry B, Noori S, Shivshankar S, et al. Cell-specific regulation of the circadian clock by BMAL1 in the paraventricular nucleus: Implications for regulation of systemic biological rhythms. Cell Rep. 2024;43:114380.","journal-title":"Cell Rep"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01788-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01788-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01788-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:53:17Z","timestamp":1789631597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01788-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1788"],"URL":"https:\/\/doi.org\/10.1038\/s41401-026-01788-8","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}